Serum Thyroid Function After Iodinated Contrast Administration

Serum Thyroid Function After Iodinated Contrast Administration in Chinese Euthyroid Adults: a Prospective Observational Study.

This study investigated the changes in serum thyroid function and urinary iodine levels before and after the use of iodinated contrast to analyze the prevalence of thyroid dysfunction in the Chinese euthyroid adults after using iodinated contrast.

Study Overview

• Status: Recruiting
• Conditions: Thyroid Dysfunction
• Intervention / Treatment: Drug: Iodinated contrast agents

Detailed Description

This study aims to monitor the thyroid function, urinary iodine level, and other indicators of patients after using iodine contrast agents, in order to analyze the prevalence of thyroid dysfunction after using iodine containing contrast agents, and investigate the impact of different iodine contrast agents on thyroid function, in order to provide evidence for the use of iodine contrast agents in clinical practice and the risk prevention of subsequent thyroid diseases.

• Study Type: Observational
• Enrollment (Estimated): 400

Contacts and Locations

• Study Contact: Name: Li Yan; Phone Number: 13719165213; Email: yanli@mail.sysu.edu.cn

Study Locations

• China
  • Guangzhou, China
    • Recruiting
    • Sun Yat-sen Memorial Hospital
    • Contact: Li Yan; Phone Number: 13719165213; Email: yanli@mail.sysu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Patients who are identified of having undergone a radiological examination use of an iodinated contrast agent in Sun Yat-sen Memorial Hospital of Sun Yat-sen University

Description

Inclusion Criteria:

• patients who use iodinated contrast agent

Exclusion Criteria:

• patients with the following diseases: malignant tumor, critical illness (admitted to ICU), mental disease, hypothalamus-pituitary disease.
• administration of anti-thyroid drugs (methimazole, propylthiouracil), levothyroxine, compound iodine solution, amiodarone, immunostaining point inhibitor, tyrosine kinase inhibitor, interferon, interleukin-6, lithium, glucocorticoids β Receptor blockers, dopamine, dobutamine, bromocriptine, octreotide, phenobarbital, phenytoin sodium, rifampicin, and carbamazepine within the past 6 months

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence rate of thyroid dysfunction after administration of iodine contrast agent.	up to 32 weeks

Collaborators and Investigators

• Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Investigators: Study Director: Li Yan, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Study record dates

Study Major Dates

• Study Start (Actual): February 15, 2023
• Primary Completion (Estimated): July 31, 2023
• Study Completion (Estimated): December 1, 2023

Study Registration Dates

• First Submitted: February 16, 2023
• First Submitted That Met QC Criteria: March 27, 2023
• First Posted (Actual): March 28, 2023

Study Record Updates

• Last Update Posted (Actual): May 30, 2023
• Last Update Submitted That Met QC Criteria: May 26, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Thyroid Diseases
• Other Study ID Numbers: SYSEC-KY-KS-2022-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No